Mouse models in oncoimmunology.
Fundamental cancer research and the development of efficacious antineoplastic treatments both rely on experimental systems in which the relationship between malignant cells and immune cells can be studied. Mouse models of transplantable, carcinogen-induced or genetically engineered malignancies - each with their specific advantages and difficulties - have laid the foundations of oncoimmunology. These models have guided the immunosurveillance theory that postulates that evasion from immune control is an essential feature of cancer, the concept that the long-term effects of conventional cancer treatments mostly rely on the reinstatement of anticancer immune responses and the preclinical development of immunotherapies, including currently approved immune checkpoint blockers. Specific aspects of pharmacological development, as well as attempts to personalize cancer treatments using patient-derived xenografts, require the development of mouse models in which murine genes and cells are replaced with their human equivalents. Such 'humanized' mouse models are being progressively refined to characterize the leukocyte subpopulations that belong to the innate and acquired arms of the immune system as they infiltrate human cancers that are subjected to experimental therapies. We surmise that the ever-advancing refinement of murine preclinical models will accelerate the pace of therapeutic optimization in patients.
Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.|Center of Clinical Investigations in Biotherapies of Cancer, CICBT1428, GRCC, 94805 Villejuif, France.
Laurence
L
Zitvogel
Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.
Jonathan M
JM
Pitt
Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France.
Romain
R
Daillère
QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; University of Queensland, Herston, QLD, Australia.
Mark J
MJ
Smyth
Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France.|University of Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France.|University of Pierre et Marie Curie, 75006 Paris, France.|Pôle de Biologie, Hôpital Européen Georges Pompidou, 75015 Paris, France.|Metabolomics and Cell Biology Platforms, GRCC, 94805 Villejuif, France.|Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.
Guido
G
Kroemer
D000826:Animal Testing Alternatives; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D004195:Disease Models, Animal; D064593:Heterografts; D006801:Humans; D007107:Immune System / Q000503:physiopathology; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology*
D002273:Carcinogens
Nature. 2007 Dec 6;450(7171):903-7
18026089
Cell. 2015 Apr 9;161(2):205-14
25860605
Science. 2013 Jan 18;339(6117):286-91
23329041
Nat Rev Cancer. 2012 Mar 22;12(4):237-51
22437869
Ann Oncol. 2016 Jul;27(7):1190-8
26912558
Cancer Res. 2015 Sep 1;75(17):3466-78
26113085
Sci Transl Med. 2016 Mar 2;8(328):328rv4
26936508
Nature. 2010 Nov 4;468(7320):98-102
20881962
J Exp Med. 2011 Mar 14;208(3):491-503
21383056
Nat Med. 2009 Oct;15(10 ):1170-8
19767732
Immunity. 2015 Sep 15;43(3):579-90
26341400
Nat Med. 2007 Sep;13(9):1050-9
17704786
Immunity. 2016 Feb 16;44(2):343-54
26872698
Inflamm Bowel Dis. 2010 Apr;16(4):559-67
19785028
Cancer Cell. 2015 Sep 14;28(3):285-95
26373277
Oncotarget. 2015 Dec 1;6(38):41204-15
26517677
Nat Med. 2015 Oct;21(10):1128-38
26444637
Nature. 2012 Feb 08;482(7385):405-9
22318517
Cancer Cell. 2004 Dec;6(6):535-8
15607957
Mol Carcinog. 2016 Jul;55(7):1187-95
26153082
Cancer Cell. 2014 Nov 10;26(5):638-52
25446897
Haematologica. 2016 Jan;101(1):5-19
26721800
Science. 2012 Sep 28;337(6102):1678-84
23019653
Nat Rev Cancer. 2012 Dec;12(12):860-75
23151605
J Exp Med. 2012 Sep 24;209(10):1869-82
22927549
J Exp Med. 2000 Sep 4;192(5):755-60
10974040
Clin Cancer Res. 2005 Feb 1;11(3):971-81
15709162
Nat Biotechnol. 2015 Apr;33(4):402-7
25774714
Cell Stem Cell. 2015 Sep 3;17(3):353-9
26299572
Cancer Immun. 2013 May 31;13:11
23885217
Oncoimmunology. 2015 Apr 1;4(10):e1022301
26451293
Adv Immunol. 2016;130:1-24
26922998
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84
19561305
Annu Rev Immunol. 2011;29:235-71
21219185
Nat Commun. 2014;5:3056
24445999
Oncogene. 2010 Jan 28;29(4):482-91
19881547
Blood. 2005 Sep 1;106(5):1565-73
15920010
Cell. 2000 Jan 7;100(1):57-70
10647931
Nat Med. 2007 Jan;13(1):54-61
17187072
Cancer Cell. 2011 Jan 18;19(1):72-85
21251614
Cancer Res. 2016 Apr 1;76(7):1746-56
26842877
Cancer Res. 2010 Oct 15;70(20):7800-9
20924111
Nat Rev Drug Discov. 2006 Sep;5(9):741-54
16915232
Science. 2011 Mar 25;331(6024):1565-70
21436444
Oncoimmunology. 2015 Jan 22;4(9):e1002721
26405589
Science. 1996 Mar 22;271(5256):1734-6
8596936
Sci Rep. 2014 Oct 16;4:6639
25322144
Cancer Immunol Immunother. 2012 Oct;61(10):1721-33
22406983
Cancer Cell. 2014 Oct 13;26(4):565-76
25220446
Blood. 2012 Dec 20;120(26):5153-62
23018643
J Exp Med. 1985 Nov 1;162(5):1665-82
3877140
Nature. 2001 Apr 26;410(6832):1111-6
11323676
Cancer Immunol Res. 2013 Dec;1(6):402-15
24778133
Blood. 2011 Dec 8;118(24):6387-91
22031859
Hum Gene Ther. 2014 Dec;25(12):1003-12
24694017
Cell. 2016 Mar 10;164(6):1233-47
26967289
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2963-8
23382238
Cancer Res. 2011 Jul 15;71(14):4809-20
21646474
Nat Rev Clin Oncol. 2016 Jul;13(7):431-46
27030078
Oncotarget. 2016 Feb 9;7(6):6448-59
26824989
Eur J Pharmacol. 2015 Jul 15;759:313-25
25814250
Nat Med. 2012 Mar 06;18(3):344-6; author reply 346
22395693
Breast Cancer Res. 2012 Mar 07;14(2):R39
22397502
Cancer Res. 2014 Sep 15;74(18):5173-83
25038231
Cancer Cell. 2012 Mar 20;21(3):402-17
22439936
Annu Rev Immunol. 2013;31:51-72
23157435
Nature. 2012 Feb 08;482(7385):400-4
22318521
Oncoimmunology. 2016 Feb 18;5(6):e1139275
27471610
Nat Rev Cancer. 2010 Jul;10(7):470-80
20574449
Nature. 2007 Feb 8;445(7128):656-60
17251933
Adv Cancer Res. 1981;34:69-106
6456650
Cancer Res. 2012 May 1;72(9):2190-6
22396496
Cancer Cell. 2016 Jul 11;30(1):147-60
27411589
Nat Protoc. 2009;4(9):1350-62
19713956
Nature. 2014 Feb 6;506(7486):52-7
24476824
J Exp Med. 1994 Jul 1;180(1):173-81
8006581
J Clin Invest. 2013 Oct;123(10):4410-22
24018560
Curr Top Microbiol Immunol. 2014;382:237-48
25116103
Nature. 2014 Nov 27;515(7528):577-81
25428507
Ann Oncol. 2014 Aug;25(8):1544-50
24608200
Pharmacogenomics. 2015;16(14):1523-6
26485224
Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13218-23
21788509
Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33
22301798
J Immunol. 2008 May 15;180(10):7009-18
18453623
Science. 2016 Apr 8;352(6282):227-31
26966191
J Invest Dermatol. 2014 Oct;134(10 ):2551-61
24751730
Nat Rev Cancer. 2012 Mar 15;12 (4):298-306
22419253
Annu Rev Immunol. 2004;22:329-60
15032581
J Clin Invest. 2012 Mar;122(3):899-910
22293174
Annu Rev Pathol. 2015;10:195-262
25621660
Cancer Cell. 2010 Nov 16;18(5):485-98
21035406
Blood. 2014 Jan 30;123(5):678-86
24326534
Science. 2015 Nov 20;350(6263):972-8
26516201
Int Immunol. 2005 Feb;17(2):133-44
15611321
Nature. 2001 Apr 26;410(6832):1107-11
11323675
N Engl J Med. 2014 Dec 4;371(23 ):2189-99
25409260
J Immunol. 2005 May 15;174(10):6477-89
15879151
PLoS One. 2014 Nov 04;9(11):e109956
25369133
Oncoimmunology. 2013 Dec 1;2(12):e26836
24498556
Cell. 2016 Apr 7;165(2):276-87
27058662
J Exp Med. 2005 Dec 19;202(12):1691-701
16365148
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
12218188
Mol Cancer. 2015 Jun 11;14 :119
26062742
Blood. 2005 Nov 1;106(9):3127-33
16037385
Blood. 2008 Dec 15;112(13):4808-17
19064740
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82
1359541